Experimental pill promises new hope for deadly pancreatic cancer
Summary
A new pill named daraxonrasib has helped people with advanced pancreatic cancer live longer. In a study, patients taking the pill lived nearly twice as long as those on chemotherapy, with fewer serious side effects.Key Facts
- Daraxonrasib blocks a mutated protein that drives tumor growth in over 90% of pancreatic cancer cases.
- The drug nearly doubled median survival time: 13.2 months versus 6.7 months for chemotherapy.
- The study involved 500 patients with metastatic pancreatic cancer resistant to prior treatments.
- Patients taking the pill reported less pain and better quality of life as tumors shrank.
- Side effects included rash and mouth sores, which affected some patients’ ability to continue treatment.
- The drug’s maker is Revolution Medicines, and the FDA is speeding up its approval process.
- The FDA allows expanded access to the drug now for eligible patients.
- Pancreatic cancer is very deadly, with about 67,000 new U.S. cases and over 52,000 deaths expected this year.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.